Patisiran uses the body's natural processes to lower the levels of TTR protein that cause TTR amyloidosis (FAP). It does so by targeting and silencing specific messenger RNA, blocking the production of TTR protein before it's made. This may help significantly reduce the level of TTR protein in the body, which may slow or halt the progression of TTR amyloidosis (FAP).